• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
VHL
Click for more information
7.69% 14.0¢

VIRAX HOLDINGS LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
VHLAppointment of Director - Mr John Morrison - 13 March 201213/03/12
VHLShare Purchase Agreement - 4G Vaccines 29 February 201201/03/12
AAY +Suspension from Official QuotationPRICE SENSITIVE01/03/12
VHLConvertible Notes - Quarterly Report 31 December 201131/01/12
VHLAppendix 3B - 10 January 201210/01/12
VHLDutchess Continuous Investment Agreement - 10 January 2012PRICE SENSITIVE10/01/12
VHLSupplemental Trust Deed, Convertible Notes, 10 Jan 201210/01/12
VHLNoteholder General Meeting - 30 December 201130/12/11
VHLSuspension from Official Quotation - VHLGPRICE SENSITIVE21/12/11
VHLChange in Substantial Shareholder20/12/11
VHLNoteholder Notice of Meeting - 30 December 201112/12/11
VHLAppendix 3B and 3Y - 23 November 201123/11/11
VHLResults of AGM 201118/11/11
VHLAGM 2011 - Chairman's Presentation18/11/11
VHLConvertible Note Quarterly Report - 30 09 201131/10/11
VHLNotice of AGM 2011 Mailing20/10/11
VHLAppendix 3B - 17 October 201117/10/11
VHLAnnual Report 30 June 201130/09/11
VHLResignation of Director - Appendix 3Z21/09/11
VHLAppendix 4E 30 June 2011PRICE SENSITIVE31/08/11
VHLConvertible Note Quarterly Report 30 06 201128/07/11
VHLTG1042 Batch Manufacturing Completed - 26 July 2011PRICE SENSITIVE26/07/11
VHLAppendix 3B and 3Y - 20 July 201120/07/11
VHLRights Offer - 19 July 2011PRICE SENSITIVE19/07/11
VHLBoardroom Radio Broadcast - 6 July 201106/07/11
VHLGeneral Meeting Results - 24 June 201124/06/11
VHLDocuments mailed to Eligible Shareholders - 22 06 201122/06/11
VHLRights Offer - Extension of Closing Date - 12 July 201120/06/11
VHLAppendix 3B - 16 June 201116/06/11
VHLTG1042 Update - MelanomaPRICE SENSITIVE10/06/11
VHLTG 1042 - Clinical Advisory Board Appointed09/06/11
VHLEligible Shareholder Offer Document Mailing - 6 June 2011PRICE SENSITIVE06/06/11
VHLBoardroom Radio Broadcast - 2 Jun 201102/06/11
VHLTG1042 SKIN CANCER IMMUNOTHERAPY - SHAREHOLDER OVERVIEW31/05/11
VHLWholesale Investor Interview - 27 May 201127/05/11
VHLConvertible Noteholder Participation in Rights Issue27/05/11
VHLNotice of General Meeting on 24 June 201126/05/11
VHLLetters to Shareholders - Entitlement Offer 26 05 201126/05/11
VHLVirax Rights Offer Documentation - 25 May 2011PRICE SENSITIVE25/05/11
VHL1 for 2 Rights Offer - 25 May 2011PRICE SENSITIVE25/05/11
VHLAppendix 3B - 4 May 201104/05/11
VHLAlpha Securities Report - 3 May 201103/05/11
VHLConvertible Note Quarterly Report 31 03 201129/04/11
VHLSky Business News Interview 22 Feb 201125/03/11
VHLAppendix 3B - 11 March 201111/03/11
VHLCorporate Update - March 201110/03/11
VHLAppendix 4D (31 Dec 2010) - 25 February 2011PRICE SENSITIVE25/02/11
VHLCo-X-Gene Sub Licence and TG4001 - 24 February 2011PRICE SENSITIVE24/02/11
VHLVirax close out of VIR201 HIV Vaccine Phase IIa TrialPRICE SENSITIVE23/02/11
VHLBoardroom Radio Broadcast - 18 February 201118/02/11
VHLAppendix 3Z - Dr Ting16/02/11
VHLExclusive License with Transgene for Novel Skin Cancer ImmunPRICE SENSITIVE14/02/11
VHLResignation of Non Executive Director11/02/11
VHLConvertible Note Quarterly Report 31 12 201028/01/11
VHLShare Trading Policy24/12/10
VHLAppendix 3B and 3Y30/11/10
VHLAGM Results - 19 November 201019/11/10
VHLAGM Presentations - Chairman and CEO Address19/11/10
VHLTerms Sheet - Skin CancerPRICE SENSITIVE12/11/10
VHLConvertible Note Quarterly Report - 30 September 201029/10/10
VHLNotice of AGM 2010 Mailing21/10/10
VHLAppendix 3B - 14 October 201014/10/10
VHLAnnual Report 201030/09/10
VHLAppendix 4EPRICE SENSITIVE31/08/10
VHLVIR201 HIV Vaccine Phase IIa Trial Results - 16 August 2010PRICE SENSITIVE16/08/10
VHLVIR201 HIV Vaccine published in AIDS JournalPRICE SENSITIVE12/08/10
VHLUpdate on VIR201 HIV Vaccine Clinical Trial - 9 August 2010PRICE SENSITIVE09/08/10
VHLConvertible Note Quarterly Report - 30 June 201023/07/10
VHLUpdate on VIR201 HIV Vaccine Clinical TrialPRICE SENSITIVE07/07/10
VHLAppendix 3B18/06/10
VHLChairman's Letter - Company Update - 14 May 201014/05/10
VHLConvertible Note Quarterly Report 31 03 201030/04/10
VHLTransgene TG4010 Exclusive OptionPRICE SENSITIVE11/03/10
VHLAppendix 3B and 3Y05/03/10
VHLAppointment of New Director01/03/10
VHLAppendix 4D - Half Year 31 December 2009PRICE SENSITIVE26/02/10
VHLResults of General Meeting25/02/10
VHLResponse to ASX Price QueryPRICE SENSITIVE23/02/10
VHLCompany Review - Alpha Securities11/02/10
VHLChange in substantial holding 9 February 201009/02/10
VHLAppendix 3B and 3Y01/02/10
VHLConvertible Notes - Quarterly Report - 29 January 2010PRICE SENSITIVE29/01/10
VHLRights Issue Update - 28 January 201028/01/10
VHLNotice of General Meeting 25 February 201027/01/10
VHLBecoming a Substantial Shareholder20/01/10
VHLRights Issues Closing Date and Status - 15 Jan 1015/01/10
VHLAppendix 3B and Section 708A(5)(e) Notice24/12/09
VHLSubsequent Placement Announcement - 23 Dec 09PRICE SENSITIVE23/12/09
VHLBoardroom Radio Broadcast - 18 Dec 200918/12/09
VHLChange Director's Interest - Appendix 3Y18/12/09
VHLAppendix 3B18/12/09
VHLNon-renounceable Rights Offer Shortfall Placement Agreement17/12/09
VHLDeferred Directors Remuneration17/12/09
VHLNon-renounceable Rights Offer Shortfall Placement AgreementsPRICE SENSITIVE16/12/09
VHLAppendix 3B10/12/09
VHLFurther Patent Protection for VIR201PRICE SENSITIVE10/12/09
VHLExtension of Closing Date Non-renounceable Rights Issue09/12/09
VHLLetter to Convertible Noteholders08/12/09
VHLAmendment to Terms of Convertible Notes Trust Deed08/12/09
VHLUS FDA Fast Track Approval of Transgene TG4010PRICE SENSITIVE03/12/09
VHLAppointment of Director - Mr John Morrison - 13 March 2012
13/03/12
VHLShare Purchase Agreement - 4G Vaccines 29 February 2012
01/03/12
AAY +Suspension from Official Quotation
01/03/12PRICE SENSITIVE
VHLConvertible Notes - Quarterly Report 31 December 2011
31/01/12
VHLAppendix 3B - 10 January 2012
10/01/12
VHLDutchess Continuous Investment Agreement - 10 January 2012
10/01/12PRICE SENSITIVE
VHLSupplemental Trust Deed, Convertible Notes, 10 Jan 2012
10/01/12
VHLNoteholder General Meeting - 30 December 2011
30/12/11
VHLSuspension from Official Quotation - VHLG
21/12/11PRICE SENSITIVE
VHLChange in Substantial Shareholder
20/12/11
VHLNoteholder Notice of Meeting - 30 December 2011
12/12/11
VHLAppendix 3B and 3Y - 23 November 2011
23/11/11
VHLResults of AGM 2011
18/11/11
VHLAGM 2011 - Chairman's Presentation
18/11/11
VHLConvertible Note Quarterly Report - 30 09 2011
31/10/11
VHLNotice of AGM 2011 Mailing
20/10/11
VHLAppendix 3B - 17 October 2011
17/10/11
VHLAnnual Report 30 June 2011
30/09/11
VHLResignation of Director - Appendix 3Z
21/09/11
VHLAppendix 4E 30 June 2011
31/08/11PRICE SENSITIVE
VHLConvertible Note Quarterly Report 30 06 2011
28/07/11
VHLTG1042 Batch Manufacturing Completed - 26 July 2011
26/07/11PRICE SENSITIVE
VHLAppendix 3B and 3Y - 20 July 2011
20/07/11
VHLRights Offer - 19 July 2011
19/07/11PRICE SENSITIVE
VHLBoardroom Radio Broadcast - 6 July 2011
06/07/11
VHLGeneral Meeting Results - 24 June 2011
24/06/11
VHLDocuments mailed to Eligible Shareholders - 22 06 2011
22/06/11
VHLRights Offer - Extension of Closing Date - 12 July 2011
20/06/11
VHLAppendix 3B - 16 June 2011
16/06/11
VHLTG1042 Update - Melanoma
10/06/11PRICE SENSITIVE
VHLTG 1042 - Clinical Advisory Board Appointed
09/06/11
VHLEligible Shareholder Offer Document Mailing - 6 June 2011
06/06/11PRICE SENSITIVE
VHLBoardroom Radio Broadcast - 2 Jun 2011
02/06/11
VHLTG1042 SKIN CANCER IMMUNOTHERAPY - SHAREHOLDER OVERVIEW
31/05/11
VHLWholesale Investor Interview - 27 May 2011
27/05/11
VHLConvertible Noteholder Participation in Rights Issue
27/05/11
VHLNotice of General Meeting on 24 June 2011
26/05/11
VHLLetters to Shareholders - Entitlement Offer 26 05 2011
26/05/11
VHLVirax Rights Offer Documentation - 25 May 2011
25/05/11PRICE SENSITIVE
VHL1 for 2 Rights Offer - 25 May 2011
25/05/11PRICE SENSITIVE
VHLAppendix 3B - 4 May 2011
04/05/11
VHLAlpha Securities Report - 3 May 2011
03/05/11
VHLConvertible Note Quarterly Report 31 03 2011
29/04/11
VHLSky Business News Interview 22 Feb 2011
25/03/11
VHLAppendix 3B - 11 March 2011
11/03/11
VHLCorporate Update - March 2011
10/03/11
VHLAppendix 4D (31 Dec 2010) - 25 February 2011
25/02/11PRICE SENSITIVE
VHLCo-X-Gene Sub Licence and TG4001 - 24 February 2011
24/02/11PRICE SENSITIVE
VHLVirax close out of VIR201 HIV Vaccine Phase IIa Trial
23/02/11PRICE SENSITIVE
VHLBoardroom Radio Broadcast - 18 February 2011
18/02/11
VHLAppendix 3Z - Dr Ting
16/02/11
VHLExclusive License with Transgene for Novel Skin Cancer Immun
14/02/11PRICE SENSITIVE
VHLResignation of Non Executive Director
11/02/11
VHLConvertible Note Quarterly Report 31 12 2010
28/01/11
VHLShare Trading Policy
24/12/10
VHLAppendix 3B and 3Y
30/11/10
VHLAGM Results - 19 November 2010
19/11/10
VHLAGM Presentations - Chairman and CEO Address
19/11/10
VHLTerms Sheet - Skin Cancer
12/11/10PRICE SENSITIVE
VHLConvertible Note Quarterly Report - 30 September 2010
29/10/10
VHLNotice of AGM 2010 Mailing
21/10/10
VHLAppendix 3B - 14 October 2010
14/10/10
VHLAnnual Report 2010
30/09/10
VHLAppendix 4E
31/08/10PRICE SENSITIVE
VHLVIR201 HIV Vaccine Phase IIa Trial Results - 16 August 2010
16/08/10PRICE SENSITIVE
VHLVIR201 HIV Vaccine published in AIDS Journal
12/08/10PRICE SENSITIVE
VHLUpdate on VIR201 HIV Vaccine Clinical Trial - 9 August 2010
09/08/10PRICE SENSITIVE
VHLConvertible Note Quarterly Report - 30 June 2010
23/07/10
VHLUpdate on VIR201 HIV Vaccine Clinical Trial
07/07/10PRICE SENSITIVE
VHLAppendix 3B
18/06/10
VHLChairman's Letter - Company Update - 14 May 2010
14/05/10
VHLConvertible Note Quarterly Report 31 03 2010
30/04/10
VHLTransgene TG4010 Exclusive Option
11/03/10PRICE SENSITIVE
VHLAppendix 3B and 3Y
05/03/10
VHLAppointment of New Director
01/03/10
VHLAppendix 4D - Half Year 31 December 2009
26/02/10PRICE SENSITIVE
VHLResults of General Meeting
25/02/10
VHLResponse to ASX Price Query
23/02/10PRICE SENSITIVE
VHLCompany Review - Alpha Securities
11/02/10
VHLChange in substantial holding 9 February 2010
09/02/10
VHLAppendix 3B and 3Y
01/02/10
VHLConvertible Notes - Quarterly Report - 29 January 2010
29/01/10PRICE SENSITIVE
VHLRights Issue Update - 28 January 2010
28/01/10
VHLNotice of General Meeting 25 February 2010
27/01/10
VHLBecoming a Substantial Shareholder
20/01/10
VHLRights Issues Closing Date and Status - 15 Jan 10
15/01/10
VHLAppendix 3B and Section 708A(5)(e) Notice
24/12/09
VHLSubsequent Placement Announcement - 23 Dec 09
23/12/09PRICE SENSITIVE
VHLBoardroom Radio Broadcast - 18 Dec 2009
18/12/09
VHLChange Director's Interest - Appendix 3Y
18/12/09
VHLAppendix 3B
18/12/09
VHLNon-renounceable Rights Offer Shortfall Placement Agreement
17/12/09
VHLDeferred Directors Remuneration
17/12/09
VHLNon-renounceable Rights Offer Shortfall Placement Agreements
16/12/09PRICE SENSITIVE
VHLAppendix 3B
10/12/09
VHLFurther Patent Protection for VIR201
10/12/09PRICE SENSITIVE
VHLExtension of Closing Date Non-renounceable Rights Issue
09/12/09
VHLLetter to Convertible Noteholders
08/12/09
VHLAmendment to Terms of Convertible Notes Trust Deed
08/12/09
VHLUS FDA Fast Track Approval of Transgene TG4010
03/12/09PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 

Top Stories

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch CuFe Ltd (ASX:CUF) has decided not to wait around for Northern Star's Crossroads mine to get up and running, selling its $4M royalty right.
Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks Copper prices slump; Trump Wall Street rally fades; US health stocks dip on RFK appointment – and much more.
Banshee's historic trenches prove rich in antimony and gold for GDM Great Divide Mining Ltd has found high-grade antimony and gold through geochemical sampling at its Banshee prospect in Queensland
NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play Empire Energy (ASX:EEG) has confirmed the NT government has delivered environmental approvals for Carpentaria.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.